Editorial: National Homoeo Recorder
Editor-in-Chief, National Homoeo Recorder
Associate Professor and Head, Dept. of Organon of Medicine and
Homoeopathic Philosophy, National Institute of Homoeopathy
On Aug 26, 2019, homoeopathy has celebrated probably its greatest triumph against its skeptics by the “release the first report” campaign, an initiative by the Homeopathy Research Institute (HRI) against Australia’s leading research institute – National Health and Medical Research Council (NHMRC). And as was expected, the draft 2012 report is far more positive than the second NHMRC Australian Report published in 2015, which has caused widespread damage to homoeopathy. The First Report found “encouraging evidence for the effectiveness of homeopathy” for five conditions, including otitis media (ear infections), upper respiratory tract infection in adults, and some side effects of cancer treatment. As Rachel Roberts, HRI Chief Executive, explains, “The first report found some good evidence that homeopathy works for certain medical conditions. More studies are needed to confirm and build on these findings, but some evidence is very different from no evidence.” NHMRC fought against releasing the First Report for 4 years, so this is a huge win for public accountability, but perhaps even more importantly, the NHMRC CEO has finally put the record straight about the second ‘Australian report’ published in 2015. Publication of NHMRC’s 2015 report triggered inaccurate headlines around the world – from the UK: “Homeopathy not effective for treating any condition” (Guardian) to the USA: “1800 studies later scientists conclude homeopathy doesn’t work”. NHMRC Chief Executive Prof Anne Kelso’s has now finally admitted that, “Contrary to some claims, the review did not conclude that homeopathy was ineffective”. It is shocking that NHMRC has never corrected this misinterpretation of their report before. When these widely inaccurate headlines first circulated in March 2015 NHMRC stayed silent. When the story hit the media again in February 2016 they said and did nothing. Even when the NHMRC 2015 report started to have a real-world impact being used to make decisions against homoeopathy in countries all around the world, they failed to step in and clarify what their report had really found – that even when the amount of evidence was drastically reduced by using their totally unjustifiable method created just for this review – the results showed the evidence for most conditions was inconclusive, not negative. The CEO finally making it clear that their report never concluded homoeopathy doesn’t work is a crucial and welcome first step towards NHMRC undoing the damage they have single-handedly caused to the homoeopathy sector worldwide.
Basking in the glory of this remarkable victory, we continue our endeavor in publishing quality researches. The task is not only rigorous and painstaking, but still innovative and we promise to continue to generate the elixir for survival of homoeopathy in long run. In this issue, we are still able in publishing two more postgraduate theses converted into original research papers. An open randomized pilot trial on 40 patients tested the effectiveness of Allium sativum mother tincture against individualized homoeopathic medicines (IH) in treatment of dyslipidemia. Following 6 months of intervention, group differences favoured IH over Allium sativum mother tincture. The other original research was a cross-sectional study to find out the prevalence of obesity in children taking excessive dietary sodium and the effect of homoeopathic medicine Natrium muriaticum on presenting complaints in such cases. The prevalence of obesity among children taking excessive dietary sodium was 29.9%. Homoeopathic medicine Natrium muriaticum offered a quality treatment for the different complaints in the best of manner for these cases. We are presenting two case reports on two very challenging conditions – vitiligo and psoriasis. Both the cases have been treated well by IH medicines over a considerable period of time. We are publishing a clinical trial protocol of an ongoing multi-centric, double-blind, randomized, placebo-controlled trial of IH medicines in geriatric depression. Alongside, this issue contains research highlights.